The influence of midazolam on plasma concentrations and pharmacokinetic parameters of lidocaine in rabbits

Pharmacological Research

Volumn 45, Issue 1, 2002, Pages 11-14

  Orszulak Michalak, D ^a   Owczarek, J ^a   Wiktorowska Owczarek, A K ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Lidocaine; Midazolam; Pharmacokinetic parameters; Rabbits

Indexed keywords

LIDOCAINE; MIDAZOLAM;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; IMMUNOFLUORESCENCE; MALE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; RABBIT; STATISTICAL ANALYSIS;

EID: 0036447185     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0879     Document Type: Article

References (33)

1. Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam. A review of its pharmacological properties and therapeutic use. Drugs 1984; 28: 519-43.
2. Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: Pharmacology and uses. Anesthesiology 1985; 62: 310-24.
3. Gelman S, Reves JG, Harris D. Circulatory responses to midazolam anesthesia: Emphasis on canine splanchnic circulation. Anesth Analg 1983; 62: 135-9.
4. Butwell NB, Ramasamy R, Lazar I, Sherry AB, Malloy CR. Effect of lidocaine on contracture, intracellular sodium, and pH in ischemic rat hearts. Am J Physiol 1993; 264: H1884-9.
5. Thomson PD, Melman KL, Richardson JA, Cohn K, Stein-brunn W, Cudihee R, Rowland M. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 1973; 78: 499-508.
6. Tucker GT, Mather LE. Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet 1979; 4: 241.
7. Piafsky KM, Borga O, Odar Cederlof I, Johansson C, Sjoqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha 1 acid glycoprotein. N Engl J Med 1978; 299: 1435-9.
8. Wood M, Wood AJ. Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther 1981; 29: 522-6.
9. Huang YS, Lee SD, Deng JF, Wu JC, Lu RH, Lin YF, Wang YJ, Lo KJ. Measuring lidocaine metabolite - Monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19: 140-7.
10. Lalka D, Griffith RK, Cronenbergere CL. The hepatic first-pass metabolism of problematic drugs. J Clin Pharmacol 1993; 33: 657-69.
11. Lonqvist PA, Herngren L. Plasma protein binding of lidocaine during hypothermic conditions. Perfusion 1993; 8: 221-4.
12. Manojlovic Z, Kopitar Z, Lenardic A, Plavsic F. Changes in plasma proteins and drug distribution in kidney and liver diseases. Lijec Vjesn 1993; 115: 366-9.
13. Belpaire FM, de Rick A, Bourda A, de Smet F, Rosseel MT, Bogaert MG. Influence of lignocaine on plasma protein binding and pharmacokinetics of verapamil in dogs. J Pharm Pharmacol 1990; 42: 45-9.
14. Douglas JH, Ross JD, Bruce DL. Delayed awakening due to lidocaine overdose. J Clin Anesth 1990; 2: 126-8.
15. Branch RA, Shand DS, Wilkinson GR, Nies AS. The reduction of lidocaine clearance by dL-propranolol: An example of haemodynamic drug interaction. J Pharmacol Exp Ther 1973; 184: 515-9.
16. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. Inhibition and kinetics of cytochrome P 450 3A activity in microsomes from rat, human, and cDNA-expressed human cytochrome p 450. Drug Metab Dispos 1996; 24: 940-7.
17. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformaion of midazolam by members of the human cytochrome P 450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 47: 1643-53.
18. Kronbach T, Mathys D, Umeno M, Gonzales FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P 450 III A4. Mol Pharmacol 1989; 36: 89-96.
19. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14-24.
20. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Oralfirst-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502.
21. Cheng H, Jusko WJ. Mean residence time of oral drugs undergoing first-pass and linear reversible metabolism. Pharm Res 1993; 10: 8-13.
22. Krzysztofiak M. Statistics (in Polish).. Warsaw: PZWL, 1981.
23. Reves JG, Kissin I, Smith LR. The effective dose of midazolam. Anesthesiology 1981; 55: 82.
24. Meyer-Wyss B, Renner E, Luo H, Scholer A. Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests. J Hepatol 1993; 19: 133-9.
25. Giaufre E, Bruguerolle B, Morrison-Lacombe G, Rousset-Rouviere B. The influence of midazolam on the plasma concentrations of bupivacaine and lidocaine after caudal injection of a mixture of the local anesthetics in children. Acta Anaesthesiol Scand 1990; 34: 44-6.
26. Schurg R, Biscoping J, Bachmann MB, Hempelmann G. Is the plasma protein binding of lidocaine modified by the simultaneous administration of midazolam? Reg Anaesth 1991; 14: 74-7.
27. Giaufre E, Bruguerolle B, Morrison-Lacombe G, Rousset-Rouviere B. Influence of midazolam on the plasma concentrations of mepivacaine after lumbar epidural injection in children. Eur J Clin Pharmacol 1990; 38: 91-2.
28. Giaufre E, Bruguerolle B, Morrison-Lacombe G, Rousset-Rouviere B. The influence of diazepam on the plasma concentrations of bupivacaine and lignocaine after caudal injection of a mixture of the local anaesthetics in children. Br J Clin Pharmacol 1988; 26: 116-8.
29. Bargetzi MJ, Aoyama T, Gonzales FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin. Pharmacol. Ther. 1989; 46: 521-7.
30. Chang KS, Feng MG, Davis RF. Midazolam produces vasodilatation by mixed endothelium-dependent and -independent mechanisms. Anesth Analg 1994; 78: 710-7.
31. Nyberg SL, Mann HJ, Hu MY, Payne WD, Hu WS, Cerra FB, Remmel RP. Extrahepatic metabolism of 4-methylumbelliferone and lidocaine in the anhepatic rabbit. Drug Metab Dispos 1996; 24: 643-8.
32. Orszulak-Michalak D. The influence of some general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs. Part IV, Lidocaine. Acta Pol Pharm - Drug Res 1995; 47: 143-52.
33. Wiktorowska A, Owczarek J, Orszulak-Michalak D. The influence of lidocaine and verapamil on haemodynamic parameters after intravenous administration of midazolam in rabbits. Pharmacol Res 1999; 39: 421-9.